To the Editor:

We thank the Humanitas COVID-19 Task Force for their interest in our manuscript and for their thoughtful comments.

In their letter, Vespa *et al.*, pointed out that our finding of a 41% prevalence of elevated liver function tests (LFTs) at admission appears to be higher than rates reported throughout Asia and particularly, the rates reported in their cohort. We reviewed and summarized the articles mentioned in their letter ([Table 1](#tbl1){ref-type="table"} ).[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6] We found that the prevalence of elevated LFTs at admission in our study was significantly lower than that reported by Vespa *et al.* [@bib2]: alanine aminotransferase (ALT, 54/417 *vs*. 78/292, *p* \<0.001), gamma-glutamyltransferase (GGT, 68/417 *vs.* 106/292, *p* \<0.001) or alkaline phosphatase (ALP, 20/417 *vs.* 28/292, *p* = 0.012) and higher for total bilirubin (TBIL, 97/417 *vs.* 31/292, *p* \<0.001), but comparable with other patient series from Asia.[@bib3], [@bib4], [@bib5], [@bib6] In fact, due to the differences in the cut-off values of elevated LFTs, underlying liver disease, and demographic factors, the prevalence of elevated LFTs in patients with COVID-19 at admission may vary widely. Of note, it has been observed that the prevalence of elevated LFTs would increase in the course of COVID-19, as seen in our study,[@bib2] which found that the time from disease onset to hospitalization significantly influenced the elevated rate of LFTs at admission.Table 1The prevalence of elevated LFTs reported in different cohorts of patients with COVID-19.Sample sizeElevated LFTs (%)Elevated LFTs, cut-off value, %Overall prognosisALTASTTBILGGTALPCai *et al.*[@bib1]41741%\>40 U/L, 13.0\>40 U/L, 18.3\>17.1 μmol/L, 23.2\>49 U/L, 16.3\>135 U/L, 4.891 (21.8%) developed severe disease during hospitalization.Vespa *et al.*[@bib2]292n/a\>50 U/L, 26.7\>50 U/L, 18.5\>1.2 mg/dl, 10.6\>55 U/L, 36.2\>150 U/L, 9.627 (9.2%) patients were transferred to ICU, and 56 (19 .2%) died.Fan *et al.*[@bib3]14737.2%\>40 U/L, 18.2\>35 U/L, 21.6\>20.5 μmol/L, 6.1\>45 U/L, 17.6\>100 U/L, 4.11 patient died.Zhang *et al.*[@bib4]115n/a\>50 U/L, 9.6\>40 U/L, 14.8\>21 μmol/L, 6.1\>57, 13.0\>120, 5.231 cases (26.96%) were evaluated as severe cases, 7 (6.09%) patients progressed to critical condition and 1 died (0.87%).Chen *et al.*[@bib5]9943.4%\>50 U/L, 28.3\>40 U/L, 35.4\>21 μmol/L, 18.2n.a.n.a.17 (17%) patients developed acute respiratory distress syndrome and 11(11%) patients died.Guan *et al.*[@bib6]1099n/a\>40 U/L, 21.3\>40 U/L, 22.2\>17.1 μmol/L, 10.5n.a.n.a.173 (15.7%) developed severe disease during hospitalization.[^1]

Because of the limited medical resources available during the beginning of the pandemic, many hospitals in high pandemic areas may have only received patients with severe disease, which would result in seeing patients with more severe liver injury. In our study, all laboratory-confirmed patients with COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 were included. Elevated LFTs were defined as the following criteria: AST or ALT values \>40 IU/L, GGT \>49 U/L, ALP \>135 U/L, and TBIL \>17.1 mol/L. Of the 417 patients in our studies, 21 (5.04%) had underlying liver disease, 123 (32%) were overweight, and 41 (10.7%) were obese at admission. The median time from disease onset to hospitalization was 4 days (IQR 1--5).

So far, older age has been acknowledged as one of the most important risk factors for deterioration due to COVID-19.[@bib7] Others at highest risk of severe COVID-19 are people with certain underlying conditions, including hypertension, cardiovascular disease, diabetes, chronic respiratory disease, cancer, renal disease, and obesity.[@bib8] Some studies have also reported that abnormal LFTs were associated with overall prognosis.[@bib3] ^,^ [@bib4] Fan *et al.*, for example, reported that baseline abnormal liver function was associated with prolonged hospital stay.[@bib3] In a recent systematic review, Kunutsor and Laukkanen conducted a meta-analysis of 16 retrospective cohort studies based in China and concluded that elevated levels of liver injury markers, particularly aminotransferases, may be associated with progression to severe disease or death.[@bib9] As seen in [Table 1](#tbl1){ref-type="table"}, the cohorts with higher mortality usually had more severe LFT changes.

In the study by Vespa *et al.*,[@bib2] elevated ALP above 150 IU/L was associated with deterioration (*p* = 0.048) and became non-significant after adjustment for age and sex (*p* = 0.13). In our study, GGT was substantially elevated at admission, whereas the increase in ALP was not pronounced in patients with COVID-19. This finding was consistent with other cohorts.[@bib3], [@bib4], [@bib5], [@bib6] The patients with COVID-19 showed elevated GGT levels and normal ALP, which may controvert the hypothesis that SARS-CoV-2 directly injures cholangiocytes. Therefore, we agree that ALP or GGT elevation may just be a marker of patient frailty or represent a stronger systemic inflammatory response to SARS-CoV-2 infection, rather than a sign of cholestatic liver injury. Liver and lung injuries share the same underlying mechanism, which may be directly or indirectly induced by SARS-CoV-2 infection. Laboratory liver function tests should thus be interpreted with caution and always in the context of a complex, multi-organ disease.
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[^1]: Comparison of categorical variables was done using the χ^2^ test or the Fisher exact test, if the cell counts were small. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; ICU, intensive care unit; LFT, liver function test; n.a., not available; TBIL, total bilirubin.
